New Insights into Protozoa Parasites: Essential Processes and Drug Targets

A special issue of Pathogens (ISSN 2076-0817). This special issue belongs to the section "Parasitic Pathogens".

Deadline for manuscript submissions: 30 April 2026 | Viewed by 1672

Special Issue Editors


E-Mail Website
Guest Editor
Laboratório de Biologia Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro 21040-360, CEP, Brazil
Interests: trypanosomatids; electron microscopy; mitochondria; oxidative stress; chemotherapy
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Laboratório de Biologia Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro 21040-360, CEP, Brazil
Interests: trypanosomatids; protozoa parasites; oxidative stress

Special Issue Information

Dear Colleagues,

Protozoa are a polyphyletic group of unicellular eukaryotes, including free-living or parasitic organisms. Among 50,000 described species, the great majority comprehends free-living cells that colonize almost all kinds of habitats, mainly feeding on organic matter. However, some species are parasites, producing disease in their hosts. In nature, protozoa parasites can be found in different hosts, such as plants, insects and other arthropods, as well as in all kind of vertebrate animals, including mammals. Since most of these diseases present anthropozoonotic potential, completely eliminating them is almost impossible, especially in wild environments. Serious and regular surveillance actions are essential if we are to avoid increases in the number of cases. Among the most important protozoa diseases for humans are Chagas disease, sleeping sickness, and leishmaniasis, caused by trypanosomatids; malaria and toxoplasmosis, caused by apicomplexa; and giardiasis, trichomoniasis, and amebiasis, caused by anaerobic protozoa. Together, these diseases affect almost all populations across the world, posing risks of infection related to geographic areas and economic and social issues, among other features. The clinical drugs used to combat these diseases are unsatisfactory, showing limited efficacy and high toxicity in many cases. The parasites’ interactions with their hosts are very complex, based on the balance between pathogens’ virulence and the host immune response. The comprehension of crucial molecular, cellular, and biochemical mechanisms, identifying their checkpoints for the success of the infection, seems to be a very reasonable approach for the development of alternative anti-protozoan drugs in the near future. In this context, the involvement of oxidative stress in protozoan infections has been demonstrated, at times aiding in cell signaling and regulation, while, at other times, causing parasites’ death. The role of antioxidant enzymes as virulence factors highlights the significance of these molecular processes, as well as the adaptive strategies employed by protozoa parasites to survive in oxidative conditions within the host, impacting the success of the infection. Conversely, autophagy serves as a physiological mechanism in eukaryotes to maintain homeostasis by degrading nonfunctional cellular components, thus minimizing the accumulation of damaged organelles and macromolecules. The participation of the autophagic pathway in protozoa has been described, particularly in relation to chemotherapy, where it can counteract the effects of drugs. The scope of this Special Issue includes distinct aspects of the protozoa–host interactions, describing cellular, molecular, and biochemical processes that relate to survival mechanisms, antioxidant defenses, and redox metabolism. We will accept reviews or original contributions.

Dr. Rubem F. S. Menna-Barreto
Dr. Ana Cristina Souza Bombaça
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • protozoa
  • parasites
  • trypanosomatids
  • apicomplexan parasites
  • anaerobic protozoa
  • chemotherapy
  • drug targets
  • protozoa–host interactions
  • autophagy
  • oxidative stress

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

27 pages, 4476 KB  
Article
Kinetics of Biomarkers for Therapeutic Assessment in Swiss Mice Infected with a Virulent Trypanosoma cruzi Strain
by María Fernanda Alves-Rosa, Doriana Dorta, Alexa Prescilla-Ledezma, Jafeth Carrasco, Leighanne Bonner, Jon J. Tamayo, Michelle G. Ng, Adelenis Vega, Melany Morales, Davis Beltran, Rosa De Jesús and Carmenza Spadafora
Pathogens 2026, 15(1), 107; https://doi.org/10.3390/pathogens15010107 - 19 Jan 2026
Viewed by 689
Abstract
Chagas disease (CD), caused by Trypanosoma cruzi, is a neglected tropical illness affecting 6–8 million people in Latin America. Reaching scholarly consensus on the host response to T. cruzi infection remains a significant challenge, primarily due to substantial heterogeneity in outcomes driven [...] Read more.
Chagas disease (CD), caused by Trypanosoma cruzi, is a neglected tropical illness affecting 6–8 million people in Latin America. Reaching scholarly consensus on the host response to T. cruzi infection remains a significant challenge, primarily due to substantial heterogeneity in outcomes driven by both the choice of animal model and the infecting parasite’s discrete typing unit (DTU). This variability complicates the evaluation and comparison of new therapeutic compounds against existing drugs, namely benznidazole and nifurtimox. This study provides a comprehensive, kinetic, multifaceted characterization of the acute infection using the highly virulent T. cruzi Y strain (TcII) in outbred Swiss mice. Here, crucial infection parameters are presented, including the optimal infective dose, the parasitemia dynamics, tissue damage markers, hematological profiles, cytokine production (Th1/Th2/Th17/Th22), and molecular parasite identification in target organs (heart, colon, esophagus, spleen, and liver) across the span of the infection. The novelty of this study lies in the kinetic integration of these parameters within a defined model; rather than presenting isolated data points, we demonstrate how the biochemical, physiological, and clinical signs and immunological responses, with the resulting organ involvement, evolve and interact over time. To complete the report, a necropsy evaluation was performed at the end of the acute, fatal infection, and it is presented here. This study fulfills a long-standing recommendation from diverse drug discovery groups for the creation of a definitive reference model to standardize preclinical testing for anti-Chagasic agents. Full article
Show Figures

Figure 1

19 pages, 6919 KB  
Article
Trypanocidal Activity of Dual Redox-Active Quinones: Trypanosoma cruzi Mitochondrion as a Target Organelle In Vitro and Anti-Inflammatory Properties In Vivo
by Raquel B. Duarte, Victor F. S. Ramos, Juliana M. C. Barbosa, Gabriel M. Oliveira, Emilay B. T. Diogo, Renata G. Almeida, Alastair J. J. Lennox, Eufrânio N. da Silva Júnior, Yasmin Pedra-Rezende and Rubem F. S. Menna-Barreto
Pathogens 2026, 15(1), 17; https://doi.org/10.3390/pathogens15010017 - 23 Dec 2025
Viewed by 549
Abstract
Chagas disease is caused by the protozoan Trypanosoma cruzi, and its current treatment is limited to the use of two nitroderivatives, benznidazole (Bz) and nifurtimox; however, their toxicity often leads to discontinuation, justifying the search for new therapeutic options. The biological activity [...] Read more.
Chagas disease is caused by the protozoan Trypanosoma cruzi, and its current treatment is limited to the use of two nitroderivatives, benznidazole (Bz) and nifurtimox; however, their toxicity often leads to discontinuation, justifying the search for new therapeutic options. The biological activity of quinones has long shown efficacy towards pathogenic microorganisms. In our previous investigations, two naphthoquinones combining ortho- and para-quinoidal moieties exhibited remarkable trypanocidal activity and presented low toxicity to host cells. Here, these two active compounds were further assessed. On trypomastigotes and epimastigotes, brominated (NQ1) and chlorinated (NQ2) nor-beta-lapachone-derived 1,2,3-triazoles were more active than Bz, presenting IC50/24 h values in the range of 0.8 to 3.1 µM. NQ1-treated epimastigotes showed a mitochondrial impairment and reactive oxygen species (ROS) production under electron microscopy and flow cytometry. The in vitro evaluation of both combinations of compounds with Bz indicated an additive interaction. In vivo, oral treatment with NQ1 reduced parasitemia in an acute model, with no evidence of toxicity. The treatment also led to a reduction in myocarditis, decreasing the PR interval in electrocardiographic analysis and reversing the sinus bradycardia caused by infection. These data suggest that T. cruzi mitochondrion are part of the NQ1 mechanism of action. In vivo, this compound presented moderate trypanocidal and promising anti-inflammatory activity. Its combination with Bz could enhance current therapeutic protocols and should be better explored in the future. Full article
Show Figures

Graphical abstract

Back to TopTop